Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CFDA Accepts Ascentage's IND Filing for Lead Drug in Hepatitis B

publication date: Jan 9, 2018

Suzhou's Ascentage Pharma reported the CFDA has accepted its IND submission for APG-1387 as a treatment for hepatitis B. The novel molecule aims to restore apoptosis (programmed cell death) and eradicate hepatitis B rather than suppressing the virus. Ascentage is developing apoptosis-promoting drugs, mostly as treatments for cancer. APG-1387 would be the first inhibitor of apoptosis inhibitors (IAP) tested in hepatitis B. Ascentage is already conducting clinical trials of APG-1387 in cancer, one of its portfolio of six clinical stage IAP candidates. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital